We re-analyse data on new diagnoses of Hepatitis C virus (HCV) for injectors in prison or attending general practices which were relied on for the cost-effectiveness of HCV testing in injectors. We use these revised estimates to suggest readily-achievable targets in Scottish general practices on HCV diagnoses for injectors born in 1956-75. Using audit data from general practices around Edinburgh, we confirm that, with effort, the suggested targets are achievable.
In their Health Technology Assessment (HTA) on the cost-effectiveness of HCV testing, Castelnuovo et al. (2006) considered both prison and general-practice based strategies, with drug treatment services as a third venue for HCV case-finding. When costs and benefits were both discounted at 3.5% (rather than at 6% and 1.5%, see National Institute for Health and Clinical Excellence (NICE), 2006), the headline cost-effectiveness for HCV case-finding doubled alarmingly to around the critical threshold of £30,000. Castelnuovo et al. (2006) confirmed the recommendation by Hutchinson et al. (2005) that it was more cost-effective for HCV case-finding to target older former IDUs. Key strategies considered in the HTA report ranged from targeting: a) all clients, b) only those with a prison or practice-documented history of IDU to c) relying on self-identified HCV risk. Self-identification could be because of ever-IDU, impending cirrhosis, deterioration in quality of life, or because prison (or drug treatment centre) offered the opportunity to check-up on blood-borne virus status (Bird et al., 1993; Gore et al., 1999; Hutchinson et al., 2004) .
In this paper, we first re-analyse the HCV test uptake(s) and HCV prevalence(s) used in the above HTA report. Castelnuovo et al. (2006) relied on published data on HCV casefinding from studies in English prisons (Skipper et al., 2003; Horne et al., 2004) and the personally-communicated data from a still-unpublished general practice study in a very deprived area of Glasgow, Possil Park (Anderson et al., 2009 ).
Next, we extrapolate from our revised figures to propose targets on HCV test uptake and case-finding for general practices. We then use six-monthly Scottish audit data from Lothian region's National Enhanced Service (NES) for Drug Users in 86 unnamed participating practices and audit data from the Muirhouse Practice, Edinburgh (over 10,000 patients) to confirm whether our targets are realistic and achievable. An initial audit at Muirhouse Practice, which has a long-standing interest in the welfare of IDUs, see Copeland et al. (2004) , was followed-up by targeted offering of HCV testing to everIDUs whose HCV status was uncertain.
METHODS
Our initial step was to re-assess the English prisons' data on HCV case-finding by Skipper et al. (2003) and Horne et al. (2004) and the Possil Park Practice data from Glasgow, as cited by Castelnuovo et al.(2006) . We did so in the light of: a) revised estimates by Bird (2000) for adult injector-inmates' prevalence and HCV prevalence in English prisons, and b) estimates of HCV prevalence and HCV test uptake for Scotland prior to 2001 by Bird et al. (2001) .
For its known ever-IDU patients aged 30-39, 40-49, or 50+ years 
RESULTS

Re-assessment of English prison-based strategies:
All prisoners new to three prisons on the Isle of Wight got an hour's health awareness lecture and could attend a health-watch clinic which offered confidential testing for blood-borne viruses and access to a care pathway leading to HCV treatment, see Skipper et al. (2003) . During one year (2000/01), 137/1,618 (8.5%) new receptions into these Isle of Wight prisons accepted HCV testing, of whom 58 (42%) were HCV antibody positive, and 41/58 (71%) had chronic HCV disease. All but two HCV antibody positives were ever-IDUs (56/58).
In English prisons around that time, 29% of adult male inmates, not 24% as citied in HTA report by Castelnuovo et al. (2006) , were estimated to have a history of IDU (Gore, 2000) and their HCV prevalence was 30% to 50% (Health Protection Agency et al., 2006; Gore et al., 2001) . We may therefore infer that at least 112 ever-IDU HCV-testees Separately, Horne et al. (2004) described the uptake of HCV screening by 3,034 entrants to Dartmoor prison in the 3.5 years from 1 January 1998. Since HCV test uptake was reported in the abstract as 12%, we assumed 364 testees (confirmed in later text as: 376).
Moreover, 16% of testees were HCV antibody positive: we assumed 58 (actually: 60).
The number of ever-IDUs among those who tested HCV antibody positive was not stated. Hutchinson (2004) has shown by capture-recapture techniques that 88% of all HCV diagnoses in Scotland are ever-IDUs. The proportion is likely to be higher in prisons and so, assuming that 95% of the HCV antibody positives in prisons were ever-IDUs, we may impute that 55/58 (or 57/60) HCV diagnoses were ever-IDUs, and thereby deduce, as in Table 2 , that HCV test uptake may have been around 18% by HCV undiagnosed everIDUs in Dartmoor prison.
In summary, the two English prison studies cited by Castelnuovo et al. (2006) had HCV test uptakes by ever-IDUs of between 15 -35%. Appropriately low (under 5%) HCV test uptake by prisoners who had never injected was also apparent. Ever-IDUs in prison had HCV prevalence of 30-50%, as in Castelnuovo's prison scenario 2 (p31), but their HCV test uptake was higher than the 12% postulated in the HTA assessment. Half of the target population (584/1,165) actually attended the practice during the 6 month period, but only 421 were offered an HCV test.
General practice-based strategies in
HCV test uptake was 28% by those to whom a test was offered (117/421, 95% CI from 23% to 32%). Fifteen out of 117 tested patients were HCV antibody positive, all were ever-IDUs bar one, and 11 of the 15 were aged 30-39 years. HCV test uptake was actually 20% by attendees (117/584: 95% CI from 17% to 23%), substantially higher than the 10% portrayed by Castelnuovo et al. (2006) .
We infer that this Glasgow practice's HCV testees included 19 ever-IDUs in line with an assumed 75% HCV prevalence, as in Bird et al. (2001) . Plausibly*, we also assume that the prevalence of HCV-undiagnosed ever-IDUs among those attending for non-urgent appointments was 6% of 6-month-attenders in this practice (35), so that HCVundiagnosed ever-IDUs' HCV test uptake would have been, encouragingly, 19/35 (54%: 95% CI from 38% to 71%), as at drug treatment services (Castelnuovo et al., 2006) . {*Scotland had an estimated 80,000 ever-IDUs in 2000, see Hutchinson (2004) : more by 2004, most aged 30-54 years, and 30% to 45% are undiagnosed HCV carriers. We assume 20,000 HCV-undiagnosed everIDUs aged 30-54 years, and so around 1.3% of the Scottish population aged 30-54 years. Prevalence may be two to four times greater in Possil Park, and ever-IDUs 50% more likely to attend their general practice than age-matched peers: hence the above 6% prevalence. Even if, rather implausibly, HCV-undiagnosed ever-IDUs had been 12% of 6-month attenders, their HCV test uptake would still have been 19/70 (27%: 95% CI from 17% to 38%).} Never-IDUs' test uptake should then have been (117-35)/(421-35) = 82/386, or 21%, and their HCV prevalence 1/82 (about 1%). Thus, HCV test uptake was around 2.5 times more likely by ever-IDUs. Both uptakes were substantially higher in the Possil Park Practice in a deprived area of Glasgow than in the English prisons studied. In those prisons, there was appropriately-counselled low HCV test uptake by men who had never injected. By contrast, the Glasgow study had promoted HCV test uptake by never-IDUs because it set out specifically to elucidate if there were unsuspected household or other routes for HCV transmission. This background rationale was not fully conveyed by Castelnuovo et al. (2006) .
Extrapolated targets for new HCV diagnoses by general practices in Scotland:
General practices in less deprived areas of Glasgow, or indeed elsewhere in Scotland, will of course have a much lower prevalence, only 2% say*, of HCV-undiagnosed 30-54 year old ever-IDU attendees than the Possil Park Practice. However, their HCV test uptake may be similar to that achieved for ever-IDUs in the Glasgow study, around 50%, and their tested HCV prevalence only moderately lower, say 67% rather than 75%.
HCV test uptake by never-IDUs should revert to an appropriately-counselled low level, as in prisons, of under 5%, but HCV prevalence would be expected to be even lower than for prisoners, say less than 1%. Since there may be 1,300 practices of similar size to the Possil Park Practice (about 4,000 patients, but injector prevalence only one third of Possil Park's), within six months to a year, at least 2,500 HCV diagnoses in known ever-IDUs born in 1956-75 should be feasible in general practices in Scotland (30% uptake, no case reviews). In the selected birth-cohorts, most will be former IDUs. This new target is about three times Scotland's estimated 850 HCV diagnoses in 2006 for all persons born in 1956-75, see Table 1 . Of those who were HCV tested, the proportion who were HCV antibody positive was 53% (95% CI: 42% to 65%) for the 30-39 year old cohort but 83% (95% CI: 74% to 91%) for older IDUs. Almost all who were HCV antibody positive had undergone PCR testing, of whom 66% were chronically infected (95% CI: 57% to 75%). Referral rate for ever-IDUs who tested PCR positive was high, and 73% had attended at least once (95% CI: 63% to 84%). Ten out of 47 PCR positive patients (21%) who attended a specialist clinic had been initiated on HCV antiviral treatment (95% CI: 10% to 33%). (Hutchinson et al., 2005) . We note that the corresponding ratio for Lothian's NES practices was 780:282 (2.8:1) or 929:358 (2.6: 1) with Muirhouse Practice added.
New data from Muirhouse Practice's audit of HCV test and treatment status for known ever-IDUs:
New data from other general practices in Lothian:
DISCUSSION
By under-estimating HCV test uptakes by undiagnosed ever-IDUs in English prisons
(around 20%, and so higher than 12% postulated in HTA report) and by undiagnosed ever-IDUs attending a general practice in a deprived area of Glasgow (95% CI from 38% to 71%: much higher than the 10% postulated in HTA report), Castelnuovo et al. (2006) have under-estimated the cost-effectiveness of HCV testing in undiagnosed ever-IDUs, including former IDUs.
Lothian's NES clients increased in number by 24% over two years but HCV diagnoses increased by 84%, a pro rata increase in the efficiency of HCV case-finding of around 20% per annum. The Lothian audit also showed that 80% to 90% of drug using clients had been asked about injecting. The increase over two years in HCV diagnoses in 1956-75 born ever-IDUs was 171, against a proposed target of 166 HCV diagnoses = 1.93 * 86 in 6 months to one year. There is additional scope for intervention, as the target is clearly stretching.
HCV diagnosis rates in excess of 10% for NES clients not known to have injected were sufficiently high that their HCV test uptake was clearly prudent. Careful inquiry is warranted into the HCV risk factors for NES clients who, prior to testing, had not declared a history of IDU and continued to deny injecting despite testing HCV antibody positive. Maternal transmission, tattooing, sexual or nosocomial HCV transmission are possible explanations.
The HCV testing intervention with ever-IDUs at Muirhouse Practice had a paradoxical effect in the 30-49 year age-group. HCV prevalence was significantly lower in the combined group of "previously-tested plus intervention-tested" ever-IDUs than in the "previously-tested" ever-IDUs alone. Either prior HCV test uptake at Muirhouse Practice had been astutely non-random or HCV-undiagnosed IDUs had been relatively protected:
perhaps as a consequence of the former. Indeed, Scotland's Needle Exchange Surveillance Initiative (Palmateer et al., 2008) When NICE revisits HCV testing, we suggest that, in addition to our revisions on HCV test uptakes, NICE should cost a PCR-based HCV test strategy for current IDUs (see Surveys, Design and Statistics Subcommittee, 2008) . In public health terms, current IDUs include a key subgroup for HCV transmission, namely: HCV seroconverters. [3,692 words] featured in Table 5 on 1956-65 and 1966-75 born drug user clients' injector history, hepatitis C test uptake and prevalence. 
